O1385
Ozagrel hydrochloride hydrate
≥98% (HPLC), solid
别名:
(E)-3-[4-(Imidazol-1-ylmethyl)phenyl]propenoic acid hydrochloride hydrate, OKY-046
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C13H12N2O2 · HCl · xH2O
化学文摘社编号:
分子量:
264.71 (anhydrous basis)
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
InChI
1S/C13H12N2O2.ClH.H2O/c16-13(17)6-5-11-1-3-12(4-2-11)9-15-8-7-14-10-15;;/h1-8,10H,9H2,(H,16,17);1H;1H2/b6-5+;;
SMILES string
O.Cl.OC(=O)\C=C\c1ccc(Cn2ccnc2)cc1
InChI key
OWIZTYOMGVTSDP-TXOOBNKBSA-N
assay
≥98% (HPLC)
form
solid
storage condition
desiccated
color
white to off-white
solubility
H2O: soluble
storage temp.
room temp
Quality Level
Application
Ozagrel hydrochloride hydrate has been used as a thromboxane synthase inhibitor:
- in high cholesterol-diet rats (HC) to test its effect on arteriolar constriction
- to pre-treat mice to test its effect on lipopolysaccharide (LPS)-induced behavioral changes
- to test its effect on arteriolar vasoconstriction in hyperglycemic mice
Biochem/physiol Actions
Ozagrel is a selective thromboxane A2 synthase (TXA2) inhibitor.
Ozagrel is useful in treating lacunar and thrombotic stroke. It blocks vasoconstriction and platelet aggregation. Ozagrel aids in improving the prostacyclin (PGI2)/ thromboxane A2 (TXA2) in the acute phase of cerebral ischemia. It improves endothelial dysfunction in L-methionine-induced hyperhomocysteinemia (HHcy)-induced vascular cognitive impairment and dementia (VCID).
存储类别
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
法规信息
新产品
此项目有
K Shinagawa et al.
British journal of pharmacology, 131(2), 266-270 (2000-09-19)
1. The purpose of this study was to investigate the involvement of thromboxane A(2) (TXA(2)) in the cough response in a guinea-pig cough model. Here, we describe results obtained using a selective TXA(2) synthetase inhibitor, ozagrel, and a selective TXA(2)
Takayuki Matsumoto et al.
Atherosclerosis, 205(1), 87-95 (2008-12-30)
Thromboxane A(2) (TXA(2)) is thought to contribute to the development of diabetic complications. We tested the hypothesis that the impaired endothelial function seen in Otsuka Long-Evans Tokushima Fatty (OLETF) rats (a type 2 diabetic model) might be improved by chronic
Yukiko Enomoto et al.
Atherosclerosis, 209(2), 415-421 (2009-11-26)
The plasma level of soluble CD40 ligand (sCD40L), which induces pro-inflammatory and pro-atherogenic responses, is known to be elevated in atherosclerotic patients. In this study, we investigated the mechanism of sCD40L release from human platelets, focusing on the involvement of
Seungjun Lee et al.
Microvascular research, 76(3), 217-223 (2008-08-23)
Retinal blood flow decreases early in the progression of diabetic retinopathy; however, the mediators and mechanisms responsible for this decrease have yet to be determined. In this study, diabetes was induced by streptozotocin in rats, and retinal blood flow was
Sang In Park et al.
Brain research, 1599, 85-92 (2015-01-04)
We investigated the neuroprotective properties of single doses of minocycline and ozagrel when administered prior to stroke. Male Sprague-Dawley rats were assigned randomly to one of the following groups: (1) control (Con) group (n=10), (2) minocycline (Mino) group (n=10), (3)
相关内容
Instructions
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持